Objective To investigate the cytotoxic effects of IL-2 combined with different dosages of sorafenib on renal cellular carcinoma cell line 786-0. Methods Renal carcinoma cell 786-0 was cultured. Then , IL-2 (20 μmol/L) combined with different dosages of sorafenib (6.9, 13.8, 20.8 μmol/L) were used to treat tumor cell 786-0. The inhibitory effect on cell proliferation was determined by MTT assay. Cell apoptosis was measured by Annexin V-FITC kit. The tumor-bearing mice models were established and divided into four groups. Results The tumor cell growth was inhibited with the time-course correlation in all groups. In the 48-hour high doses group, the inhibitory rate was up to (74.67±1.87) %. The rates of cell proliferation inhibition and cell apoptosis were higher in the high dosages group than those in the other groups. Conclusions Immunotherapy combined with target therapy could significantly inhibit the growth of renal cellular carcinoma. But we should find a proper dosage, which could improve the clinical effect and reduce the adverse effect.%目的：观察白细胞介素-2（IL-2）联合不同剂量索拉菲尼对肾癌786-0细胞的体内外杀伤效应。方法：取肾癌细胞株进行培养，以 IL-2（20μmol/L）联合不同剂量索拉菲尼（6．9、13．8、20．8μmol/L）作用于肾癌细胞株，MTT法检测各组对肾癌细胞的抑制作用，AnnexinV-FITC 试剂盒检测各组对其凋亡率的影响。建立裸鼠皮下移植瘤模型，观察各组对移植瘤生长的抑制作用及荷瘤小鼠的耐受性。结果：各组均表现出对肾癌细胞的抑制作用，呈现剂量-时间依赖性，以高剂量组48 h的抑制率最高，达到（74．67±1．87）％。同时高剂量组表现出更明显的抑制肿瘤生长及诱导肿瘤凋亡的作用，但小鼠的药物耐受性也明显下降。结论：免疫治疗联合靶向治疗能够很好地抑制肾癌的生长，但需合理调整两药的使用剂量，才能取得满意疗效。
展开▼
